HCV reinfection studies and the door to vaccine development

Journal of Hepatology

Volumn 51, Issue 4, 2009, Pages 628-631

  Grebely, Jason ^a   Thomas, David L ^b,c   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C VACCINE;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMPANZEE; EDITORIAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNIZATION; PRIORITY JOURNAL; PROPHYLAXIS; REINFECTION; SEROCONVERSION; SUPERINFECTION; T CELL DEPLETION; VACCINE PRODUCTION; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; ANIMALS; HEPATITIS C; HUMANS; PAN TROGLODYTES; RECURRENCE; VIRAL HEPATITIS VACCINES;

EID: 69949177105     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.07.002     Document Type: Editorial

References (35)

1. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., and Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244 (1989) 359-362
2. Diepolder H.M., Zachoval R., Hoffmann R.M., Wierenga E.A., Santantonio T., Jung M.C., et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346 (1995) 1006-1007
3. Gruner N.H., Gerlach T.J., Jung M.C., Diepolder H.M., Schirren C.A., Schraut W.W., et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 181 (2000) 1528-1536
4. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191 (2000) 1499-1512
5. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98 (1996) 706-714
6. Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C., and Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194 (2001) 1395-1406
7. Bowen D.G., and Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 (2005) 946-952
8. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6 (2000) 578-582
9. Prince A.M., Brotman B., Huima T., Pascual D., Jaffery M., and Inchauspe G. Immunity in hepatitis C infection. J Infect Dis 165 (1992) 438-443
10. Farci P., Alter H.J., Govindarajan S., Wong D.C., Engle R., Lesniewski R.R., et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 258 (1992) 135-140
11. Bassett S.E., Guerra B., Brasky K., Miskovsky E., Houghton M., Klimpel G.R., et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 33 (2001) 1479-1487
12. Major M.E., Mihalik K., Puig M., Rehermann B., Nascimbeni M., Rice C.M., et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 76 (2002) 6586-6595
13. Nascimbeni M., Mizukoshi E., Bosmann M., Major M.E., Mihalik K., Rice C.M., et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol 77 (2003) 4781-4793
14. Lanford R.E., Guerra B., Chavez D., Bigger C., Brasky K.M., Wang X.H., et al. Cross-genotype immunity to hepatitis C virus. J Virol 78 (2004) 1575-1581
15. Prince A.M., Brotman B., Lee D.H., Pfahler W., Tricoche N., Andrus L., et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J Infect Dis 192 (2005) 1701-1709
16. Shoukry N.H., Grakoui A., Houghton M., Chien D.Y., Ghrayeb J., Reimann K.A., et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 197 (2003) 1645-1655
17. Grakoui A., Shoukry N.H., Woollard D.J., Han J.H., Hanson H.L., Ghrayeb J., et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302 (2003) 659-662
18. Lai M.E., Mazzoleni A.P., Argiolu F., De Virgilis S., Balestrieri A., Purcell R.H., et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 343 (1994) 388-390
19. Tisone G., Baiocchi L., Orlando G., Palmieri G.P., Pisani F., Rapicetta M., et al. Hepatitis C reinfection after liver transplantation in relation to virus genotype. Transplant Proc 31 (1999) 490-491
20. Proust B., Dubois F., Bacq Y., Le Pogam S., Rogez S., Levillain R., et al. Two successive hepatitis C virus infections in an intravenous drug user. J Clin Microbiol 38 (2000) 3125-3127
21. Payen J.L., Izopet J., Barange K., Puel J., Selves J., and Pascal J.P. [Hepatitis C virus reinfection after an intravenous drug injection]. Gastroenterol Clin Biol 22 (1998) 469-470
22. Asselah T., Vidaud D., Doloy A., Boyer N., Martinot M., Vidaud M., et al. Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy. Gut 52 (2003) 900-902
23. den Hollander J.G., Rijnders B.J., van Doornum G.J., and van der Ende M.E. Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy. AIDS 19 (2005) 639-640
24. Gerlach J.T., Diepolder H.M., Zachoval R., Gruener N.H., Jung M.C., Ulsenheimer A., et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125 (2003) 80-88
25. Osburn WO, Fisher BE, Dowd KA, Melendez G, Liu L, Ray SC, et al. Protective immunity afforded by clearance of nai{dotless}̈ve HCV infection is associated with diminished secondary viremia and generation of new cellular immune responses during reinfection. In: Programs and abstracts of the 13th international symposium on viral hepatitis and liver disease; Washington, DC, USA. 2009.
26. Aitken C.K., Tracy S.L., Revill P., Bharadwaj M., Bowden D.S., Winter R.J., et al. Consecutive infections and clearances of different hepatitis C virus genotypes in an injecting drug user. J Clin Virol 41 (2008) 293-296
27. Aberle J.H., Formann E., Steindl-Munda P., Weseslindtner L., Gurguta C., Perstinger G., et al. Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection. J Clin Virol 36 (2006) 24-31
28. Mehta S.H., Cox A., Hoover D.R., Wang X.H., Mao Q., Ray S., et al. Protection against persistence of hepatitis C. Lancet 359 (2002) 1478-1483
29. Micallef J.M., Macdonald V., Jauncey M., Amin J., Rawlinson W., van Beek I., et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 14 (2007) 413-418
30. Grebely J., Conway B., Raffa J.D., Lai C., Krajden M., and Tyndall M.W. Hepatitis C virus reinfection in injection drug users. Hepatology 44 (2006) 1139-1145
31. Aitken C.K., Lewis J., Tracy S.L., Spelman T., Bowden D.S., Bharadwaj M., et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 48 (2008) 1746-1752
32. van de Laar T.J.W., Molenkamp R., van den Berg C., Schinkel J., Beld M.G.H.M., Prins M., et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol 51 (2009) 667-674
33. Khakoo S.I., Thio C.L., Martin M.P., Brooks C.R., Gao X., Astemborski J., et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305 (2004) 872-874
34. Mosley J.W., Operskalski E.A., Tobler L.H., Buskell Z.J., Andrews W.W., Phelps B., et al. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat 15 (2008) 120-128
35. Laskus T., Wang L.F., Radkowski M., Vargas H., Nowicki M., Wilkinson J., et al. Exposure of hepatitis C virus (HCV) RNA-positive recipients to HCV RNA-positive blood donors results in rapid predominance of a single donor strain and exclusion and/or suppression of the recipient strain. J Virol 75 (2001) 2059-2066